 |
424 Diseases |  |
809 Trials |
|
809 Trials |  |
14393 News |  |
| «12...166167168169170171172173174175176...235236» |
- | Enrollment change, Trial withdrawal: QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy (clinicaltrials.gov) - Aug 28, 2019
P1/2, N=0, Withdrawn, Sponsor: NantKwest, Inc.
N=67 --> 0 | Not yet recruiting --> Withdrawn
- | Enrollment change, Trial withdrawal: QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors (clinicaltrials.gov) - Aug 28, 2019
P1/2, N=0, Withdrawn, Sponsor: NantKwest, Inc.
N=67 --> 0 | Not yet recruiting --> Withdrawn N=85 --> 0 | Not yet recruiting --> Withdrawn
- | Enrollment change, Trial withdrawal: QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy (clinicaltrials.gov) - Aug 28, 2019
P1/2, N=0, Withdrawn, Sponsor: NantKwest, Inc.
N=85 --> 0 | Not yet recruiting --> Withdrawn N=113 --> 0 | Not yet recruiting --> Withdrawn
- | Enrollment change, Trial withdrawal: QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC (clinicaltrials.gov) - Aug 28, 2019
P1/2, N=0, Withdrawn, Sponsor: NantKwest, Inc.
N=113 --> 0 | Not yet recruiting --> Withdrawn N=79 --> 0 | Not yet recruiting --> Withdrawn
- | ETBX-061 / ImmunityBio, NK92-CD16-158V / ImmunityBio, Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Enrollment change, Trial withdrawal: QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL (clinicaltrials.gov) - Aug 28, 2019
P1/2, N=0, Withdrawn, Sponsor: NantKwest, Inc.
N=79 --> 0 | Not yet recruiting --> Withdrawn N=67 --> 0 | Not yet recruiting --> Withdrawn
- | Enrollment change, Trial withdrawal: QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy (clinicaltrials.gov) - Aug 28, 2019
P1/2, N=0, Withdrawn, Sponsor: NantKwest, Inc.
N=67 --> 0 | Not yet recruiting --> Withdrawn N=67 --> 0 | Not yet recruiting --> Withdrawn
- | Enrollment change, Trial withdrawal: QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy (clinicaltrials.gov) - Aug 28, 2019
P1/2, N=0, Withdrawn, Sponsor: NantKwest, Inc.
N=67 --> 0 | Not yet recruiting --> Withdrawn N=67 --> 0 | Not yet recruiting --> Withdrawn
- | Enrollment change, Trial withdrawal, Metastases: QUILT-3.088: NANT Pancreatic Cancer Vaccine (clinicaltrials.gov) - Aug 28, 2019
P2, N=0, Withdrawn, Sponsor: NantKwest, Inc.
N=67 --> 0 | Not yet recruiting --> Withdrawn N=1064 --> 0 | Not yet recruiting --> Withdrawn
- | Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date, Metastases: QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine (clinicaltrials.gov) - Aug 28, 2019
P1/2, N=0, Withdrawn, Sponsor: NantKwest, Inc.
N=1064 --> 0 | Not yet recruiting --> Withdrawn N=382 --> 0 | Trial completion date: Dec 2022 --> Aug 2019 | Active, not recruiting --> Withdrawn | Trial primary completion date: Jul 2020 --> Aug 2019
- | Biomarker, New P2/3 trial, New trial: COBRA: Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery (clinicaltrials.gov) - Aug 28, 2019
P, N=0, Withheld, Sponsor: [Redacted]
- | Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / BMS
New P2 trial, Tumor mutational burden: NIVACOR: Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients (clinicaltrials.gov) - Aug 28, 2019
P2, N=70, Not yet recruiting, Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica
- | Herceptin (trastuzumab) / Roche
Retrospective data, Journal: Safety and efficacy of a docetaxel-5FU-oxaliplatin regimen with or without trastuzumab in neoadjuvant treatment of localized gastric or gastroesophageal junction cancer: A retrospective study. (Pubmed Central) - Aug 23, 2019
TeFOX regimen could be safely administrated in perioperative treatment of localized GC. TeFOX and the FLOT regimen have comparable efficacy and safety profiles.
- | Removab (catumaxomab) / NeoPharm, Trion
Clinical, P2 data, Journal: Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer. (Pubmed Central) - Aug 23, 2019
Addition of catumaxomab to systemic chemotherapy was feasible and tolerable in advanced GC. Although the primary endpoint could not be demonstrated, results are promising for future investigations integrating intraperitoneal immunotherapy into a multimodal treatment strategy.
- | leucovorin calcium / generics, fluorouracil / generics
Journal: Preoperative FOLFOX in resectable locally advanced rectal cancer can be a safe and promising strategy: the R-NAC-01 study. (Pubmed Central) - Aug 22, 2019
Although the primary endpoint could not be demonstrated, results are promising for future investigations integrating intraperitoneal immunotherapy into a multimodal treatment strategy. Surgery after four courses of mFOLFOX6 chemotherapy can be a safe and promising strategy for patients with locally advanced rectal cancer.
- | Herceptin (trastuzumab) / Roche, paclitaxel / Generic Mfg., Opdivo (nivolumab) / Ono Pharma, BMS
Biomarker, Clinical, Journal, PD(L)-1 Biomarker, IO Biomarker: Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica. (Pubmed Central) - Aug 21, 2019
Surgery after four courses of mFOLFOX6 chemotherapy can be a safe and promising strategy for patients with locally advanced rectal cancer. Molecular analysis and personalized therapy can help optimize treatment in difficult-to-treat cancers.
- | oxaliplatin / generics, leucovorin calcium / generics, fluorouracil / generics
Clinical, Journal: L-Carnosine protects against Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: A perspective on targeting Nrf-2 and NF-κB pathways. (Pubmed Central) - Aug 21, 2019
Molecular analysis and personalized therapy can help optimize treatment in difficult-to-treat cancers. L-Carnosine exerted a neuroprotective effect against oxaliplatin-induced peripheral neuropathy in colorectal cancer patients by targeting Nrf-2 and NF-κB pathways.
- | Trial completion date, Metastases: Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov) - Aug 21, 2019
P2, N=44, Active, not recruiting, Sponsor: University of Florida
L-Carnosine exerted a neuroprotective effect against oxaliplatin-induced peripheral neuropathy in colorectal cancer patients by targeting Nrf-2 and NF-κB pathways. Trial completion date: Jul 2019 --> Jan 2020
- | oxaliplatin / Generic mfg., irinotecan / Generic mfg.
Trial completion, Trial primary completion date, Surgery, Post-surgery: A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma (clinicaltrials.gov) - Aug 21, 2019
P2, N=22, Completed, Sponsor: NorthShore University HealthSystem
Trial completion date: Jul 2019 --> Jan 2020 Active, not recruiting --> Completed | Trial primary completion date: Mar 2018 --> Aug 2018
- | oxaliplatin / generics, leucovorin calcium / generics, fluorouracil / generics
Clinical, Journal: Expressions of 10 genes as candidate predictors of recurrence in stage III colon cancer patients receiving adjuvant oxaliplatin-based chemotherapy. (Pubmed Central) - Aug 20, 2019
Although several prediction models of tumor recurrence have been reported for CC, the set of 10 genes that the present study identified may be useful to predict the risk of recurrence in stage III CC patients receiving oxaliplatin-based adjuvant chemotherapy. Based on these results, high-risk patients with CC should be carefully observed to detect tumor recurrence during the follow-up period.
- | Enrollment change, Trial termination: Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors (clinicaltrials.gov) - Aug 20, 2019
P3, N=27, Terminated, Sponsor: Tufts Medical Center
Based on these results, high-risk patients with CC should be carefully observed to detect tumor recurrence during the follow-up period. N=190 --> 27 | Suspended --> Terminated; PI departure from coordinating institution
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Phase classification, Metastases: HAIC Using Oxaliplatin Plus Fluorouracil/Leucovorin for Patients With Locally Advanced HCC (clinicaltrials.gov) - Aug 20, 2019
P=N/A, N=0, Approved for marketing, Sponsor: Ming Zhao
N=190 --> 27 | Suspended --> Terminated; PI departure from coordinating institution Phase classification: P2 --> P=N/A
- | Enrollment open, Metastases: GEMPAX: Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Aug 19, 2019
P3, N=210, Recruiting, Sponsor: UNICANCER
Phase classification: P2 --> P=N/A Not yet recruiting --> Recruiting
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
New P2 trial: IMAGINE: Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG (clinicaltrials.gov) - Aug 19, 2019
P2, N=88, Not yet recruiting, Sponsor: Jan Ellermeier
- | sapitinib (AZD8931) / AstraZeneca
Trial completion, Trial completion date, Trial primary completion date, Combination therapy: PANTHER: Phase I/II Trial of Antagonism of HER in GI Cancer (clinicaltrials.gov) - Aug 19, 2019
P2, N=24, Completed, Sponsor: University College, London
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Aug 2019 | Trial primary completion date: Aug 2020 --> Aug 2019
- | Stivarga (regorafenib) / Bayer
Enrollment closed, Enrollment change, Monotherapy, Metastases: Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC (clinicaltrials.gov) - Aug 18, 2019
P2, N=2, Active, not recruiting, Sponsor: Fox Chase Cancer Center
Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Aug 2019 | Trial primary completion date: Aug 2020 --> Aug 2019 Recruiting --> Active, not recruiting | N=15 --> 2
- | Zaltrap (ziv-aflibercept IV) / Sanofi, Regeneron
Clinical, P2 data, Journal: Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first‑line therapy for metastatic colorectal cancer: GERCOR VELVET phase II study. (Pubmed Central) - Aug 17, 2019
Aflibercept in combination with 5‑fluorouracil (5‑FU)/irinotecan improves overall survival in the second‑line therapy of patients with metastatic colorectal cancer (mCRC)...Patients with previously untreated, unresectable, evaluable or measurable mCRC, with an age ≥18 years, and an ECOG performance status of 0‑2 received 6 cycles of modified FOLFOX7 (5‑FU/folinic acid and oxaliplatin) with aflibercept at 4 mg/kg every 2 weeks followed by maintenance therapy with fluoropyrimidine with aflibercept until disease progression or limiting toxicity...On the whole, this study demonstrates the efficacy of aflibercept in combination with an oxaliplatin‑based regimen in the first‑line therapy of patients with mCRC. A strict monitoring of blood pressure and immediate management of hypertension during therapy is mandatory.
- | leucovorin calcium / generics, fluorouracil / generics
Journal: Remarkably higher efficacy and a wider safety window for nonfrontline over first-line drug combinations in the adenocarcinoma Colo 320DM cell line. (Pubmed Central) - Aug 17, 2019
Human mesenchymal stem cells could be an excellent alternative to laboratory animals, when testing the safety profiles of drugs. The most promising combinations of non-frontline drugs to treat CRC are Carbo/Cispl/ Asp and Carbo/Cispl/DIM.
- | leucovorin calcium / generics, fluorouracil / generics
Journal: Impact of pelvic bone marrow irradiation on the hematological toxicity of subsequent chemotherapy in rectal cancer. (Pubmed Central) - Aug 17, 2019
We found no influence of dose-volume distribution on TOX2 in GLM and no significant differences in mean dose, mean V20%, and mean V40% for PBM, IBM, LSM, and LPM between patients who experienced TOX2 and those who did not. To conclude, no relationship between doses received by PBM in preoperative radio(chemo)therapy in rectal cancer and hematological tolerance of subsequent FOLFOX-4 chemotherapy was found.
- | Avastin (bevacizumab) / Roche
Clinical, P2/3 data, Journal, Head-to-Head: Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parralel-group, phase II-III, randomised, superiority study (CAIRO6). (Pubmed Central) - Aug 16, 2019
P2/3
To conclude, no relationship between doses received by PBM in preoperative radio(chemo)therapy in rectal cancer and hematological tolerance of subsequent FOLFOX-4 chemotherapy was found. This is the first randomised study that prospectively compares oncological outcomes of perioperative systemic therapy and CRS-HIPEC with upfront CRS-HIPEC alone for isolated resectable colorectal PM.
- | leucovorin calcium / generics, fluorouracil / generics
Clinical, Clinical data, Journal: Hepatic Resection Following Selective Internal Radiation Therapy for Colorectal Cancer Metastases in the FOXFIRE Clinical Trial: Clinical Outcomes and Distribution of Microspheres. (Pubmed Central) - Aug 16, 2019
This study promotes the feasibility of hepatic resection following SIRT. Resin microspheres appear to preferentially distribute at the tumour periphery and may enhance tumour regression.
- | Trial completion date, Trial primary completion date, Combination therapy, Metastases: PanCO: A Pilot Study of OncoSil (clinicaltrials.gov) - Aug 15, 2019
P=N/A, N=50, Active, not recruiting, Sponsor: OncoSil Medical Limited
Resin microspheres appear to preferentially distribute at the tumour periphery and may enhance tumour regression. Trial completion date: Feb 2020 --> Jun 2020 | Trial primary completion date: Feb 2020 --> Jun 2020
- | Vectibix (panitumumab) / Amgen
Enrollment closed: Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer (clinicaltrials.gov) - Aug 15, 2019
P2, N=75, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Feb 2020 --> Jun 2020 | Trial primary completion date: Feb 2020 --> Jun 2020 Recruiting --> Active, not recruiting
- | leucovorin calcium / Generic mfg.
New P2 trial: Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium (clinicaltrials.gov) - Aug 15, 2019
P2, N=80, Not yet recruiting, Sponsor: Phoenix Children's Hospital
- | leucovorin calcium / Generic mfg.
New P2 trial: Treatment of Social and Language Deficits With Leucovorin for Young Children With Autism (clinicaltrials.gov) - Aug 15, 2019
P2, N=80, Not yet recruiting, Sponsor: Phoenix Children's Hospital
- | leucovorin calcium / generics
Clinical, Journal: Prenatal therapy with pyrimethamine + sulfadiazine versus spiramycin to reduce placental transmission of toxoplasmosis : A multicenter, randomized trial. (Pubmed Central) - Aug 15, 2019
There were also no fetal cerebral toxoplasmosis lesions in the PS group. These promising results encourage further research on chemoprophylaxis to prevent congenital toxoplasmosis.
- | Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Trial primary completion date, Combination therapy: A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors (clinicaltrials.gov) - Aug 15, 2019
P1, N=430, Recruiting, Sponsor: Hoffmann-La Roche
These promising results encourage further research on chemoprophylaxis to prevent congenital toxoplasmosis. Trial primary completion date: Jul 2019 --> Jan 2021
- | eftozanermin alfa (ABBV-621) / AbbVie, Apogenix
Trial completion date, Trial primary completion date: A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies (clinicaltrials.gov) - Aug 15, 2019
P1, N=205, Recruiting, Sponsor: AbbVie
Trial primary completion date: Jul 2019 --> Jan 2021 Trial completion date: Jul 2020 --> Dec 2021 | Trial primary completion date: Jul 2020 --> Feb 2021
- | dactinomycin / Generic mfg.
Enrollment change: Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia (clinicaltrials.gov) - Aug 14, 2019
P3, N=57, Active, not recruiting, Sponsor: Gynecologic Oncology Group
Trial completion date: Jul 2020 --> Dec 2021 | Trial primary completion date: Jul 2020 --> Feb 2021 N=384 --> 57
- | thioguanine / Generic mfg., dasatinib / Generic mfg.
Enrollment closed: AALL1131: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations (clinicaltrials.gov) - Aug 14, 2019
P3, N=5956, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=384 --> 57 Suspended --> Active, not recruiting
- | bemarituzumab (AMG 552) / Amgen
Trial completion date, Trial primary completion date, Metastases: FIGHT: A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer (clinicaltrials.gov) - Aug 14, 2019
P1a, N=10, Active, not recruiting, Sponsor: Five Prime Therapeutics, Inc.
Suspended --> Active, not recruiting Trial completion date: Feb 2019 --> Jul 2024 | Trial primary completion date: Jul 2018 --> Jul 2022
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: BTCRC-GI15-015: FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma (clinicaltrials.gov) - Aug 14, 2019
P2, N=39, Recruiting, Sponsor: Al B. Benson, III, MD
Trial completion date: Feb 2019 --> Jul 2024 | Trial primary completion date: Jul 2018 --> Jul 2022 Trial completion date: Jun 2020 --> Jun 2021 | Trial primary completion date: Jun 2019 --> Jun 2020
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Trial initiation date, Combination therapy, Metastases: Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma: (clinicaltrials.gov) - Aug 14, 2019
P2, N=28, Not yet recruiting, Sponsor: Big Ten Cancer Research Consortium
Trial completion date: Jun 2020 --> Jun 2021 | Trial primary completion date: Jun 2019 --> Jun 2020 Initiation date: Jun 2019 --> Oct 2019
- | Viracept (nelfinavir) / ViiV Healthcare, Roche
Trial completion, Metastases: Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Aug 11, 2019
P1, N=46, Completed, Sponsor: University of Nebraska
Initiation date: Jun 2019 --> Oct 2019 Active, not recruiting --> Completed
- | Enrollment change: NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS) (clinicaltrials.gov) - Aug 9, 2019
P3, N=540, Recruiting, Sponsor: Cancer Trials Ireland
Active, not recruiting --> Completed N=366 --> 540
- | Vectibix (panitumumab) / Amgen
Enrollment change, Trial completion date, Trial primary completion date, Real-world evidence: Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix (clinicaltrials.gov) - Aug 8, 2019
P=N/A, N=606, Recruiting, Sponsor: iOMEDICO AG
N=366 --> 540 N=1222 --> 606 | Trial completion date: Jan 2023 --> Mar 2024 | Trial primary completion date: Jan 2023 --> Mar 2024
- | Avastin (bevacizumab) / Roche
Clinical, Journal: Treatment patterns and survival outcomes for patients receiving second-line treatment for metastatic colorectal cancer in the USA. (Pubmed Central) - Aug 8, 2019
Patients diagnosed with metastatic colorectal cancer lived less than 2 years in this real-world database. While the time to initiation of second-line therapy was by definition longer among patients without rapidly progressing disease, survival outcomes were comparable from initiation of second-line therapy.
- | leucovorin calcium / generics, fluorouracil / generics, irinotecan / generics
Biomarker, Clinical, Observational data, Journal: FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan. (Pubmed Central) - Aug 8, 2019
A high mGPS may be associated with poor survival in patients with locally advanced pancreatic cancer who receive FOLFIRINOX. This study was registered at the UMIN Clinical Trials Registry (UMIN000014658).
- | leucovorin calcium / generics, fluorouracil / generics, capecitabine / generics
Retrospective data, Journal: Oncologic outcomes after adjuvant chemotherapy with capecitabine compared to 5-fluorouracil/leucovorin for geriatric stage II colon cancer: a retrospective cohort study. (Pubmed Central) - Aug 8, 2019
This study was registered at the UMIN Clinical Trials Registry (UMIN000014658). Capecitabine is a safe regimen in terms of oncologic outcomes compared with FL in older patients with stage II colon cancer.
- | leucovorin calcium / generics, fluorouracil / generics, irinotecan / generics
Clinical, Journal, HEOR: FOLFIRINOX is a cost-effective combination chemotherapy in first-line for advanced pancreatic ikcancer. (Pubmed Central) - Aug 8, 2019
Capecitabine is a safe regimen in terms of oncologic outcomes compared with FL in older patients with stage II colon cancer. Combining pharmacological costs with the measure of efficacy represented by PFS, FOLFIRINOX is a cost-effective first-line for advanced pancreatic cancer.
- Avastin (bevacizumab) / Roche
Bevacizumab-Linked Acute Pancreatitis: A Case Report (Exhibit Halls 3 and 4 (Street Level)) - Aug 8, 2019 - Abstract #ACG2019ACG_2330;
Case Description/ We herein present the case of a 78-year-old man with metastatic colon cancer treated with Leucovorin, 5- fluorouracil and irinotecan plus bevacizumab...Due to the widespread use of bevacizumab in patients with a variety of malignancies, it is important that health care providers be aware of acute pancreatitis as a possible side effect of bevacizumab. Our aim is to raise awareness among gastroenterologists and other medical professionals to consider acute pancreatitis as a possible side effect of bevacizumab.